Caladrius is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing.
August 6, 2015
Caladrius Biosciences, Inc. Announces Second Quarter 2015 Financial Results and Provides Corporate Update
June 5, 2015
Pipeline & Capabilities
Caladrius is a company combining a leading cell therapy service provider with a development pipeline including late-stage clinical programs based on proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.